Israel Englander Werewolf Therapeutics, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 784,617 shares of HOWL stock, worth $823,847. This represents 0.0% of its overall portfolio holdings.

Number of Shares

784,617

Previous 596,289 31.58%

Holding current value

$823,847

Previous $882,000 13.72%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.97 - $1.68 $182,678 - $316,391	188,328 Added 31.58%	784,617 $761,000
Q4 2024 Feb 14, 2025	SELL	$1.48 - $3.63 $1.08 Million - $2.64 Million	-727,484 Reduced 54.96%	596,289 $882,000
Q3 2024 Nov 14, 2024	BUY	$1.71 - $2.95 $365,042 - $629,751	213,475 Added 19.23%	1,323,773 $2.81 Million
Q2 2024 Aug 14, 2024	BUY	$2.34 - $6.75 $1.28 Million - $3.68 Million	544,881 Added 96.37%	1,110,298 $2.71 Million
Q1 2024 May 15, 2024	BUY	$3.92 - $7.91 $474,547 - $957,568	121,058 Added 27.24%	565,417 $3.66 Million
Q4 2023 Feb 14, 2024	SELL	$1.78 - $4.15 $738,500 - $1.72 Million	-414,888 Reduced 48.29%	444,359 $1.72 Million
Q2 2023 Aug 14, 2023	SELL	$2.31 - $3.65 $550,013 - $869,068	-238,101 Reduced 21.7%	859,247 $2.62 Million
Q1 2023 May 15, 2023	BUY	$1.98 - $4.3 $512,911 - $1.11 Million	259,046 Added 30.9%	1,097,348 $2.85 Million
Q4 2022 Feb 14, 2023	BUY	$1.53 - $4.73 $499,841 - $1.55 Million	326,694 Added 63.86%	838,302 $1.72 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $7.42 $1.09 Million - $1.95 Million	262,691 Added 105.53%	511,608 $2.31 Million

Others Institutions Holding HOWL

# of Institutions

Shares Held

27.4M

Call Options Held

300

Put Options Held

13.6K

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $31M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account